No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	carfilzomib Sensitive: A1 - Approval carfilzomib Sensitive : A1	carfilzomib Sensitive: A1 - Approval carfilzomib Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	bortezomib + panobinostat Sensitive: A1 - Approval bortezomib + panobinostat Sensitive : A1	bortezomib + panobinostat Sensitive: A1 - Approval bortezomib + panobinostat Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	bortezomib + pegylated liposomal doxorubicin Sensitive: A1 - Approval bortezomib + pegylated liposomal doxorubicin Sensitive : A1	bortezomib + pegylated liposomal doxorubicin Sensitive: A1 - Approval bortezomib + pegylated liposomal doxorubicin Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	lenalidomide + ixazomib Sensitive: A1 - Approval lenalidomide + ixazomib Sensitive : A1	lenalidomide + ixazomib Sensitive: A1 - Approval lenalidomide + ixazomib Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	bortezomib Sensitive: A1 - Approval bortezomib Sensitive : A1	bortezomib Sensitive: A1 - Approval bortezomib Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	lenalidomide + carfilzomib Sensitive: A1 - Approval lenalidomide + carfilzomib Sensitive : A1	lenalidomide + carfilzomib Sensitive: A1 - Approval lenalidomide + carfilzomib Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	rituximab + bortezomib Sensitive: A1 - Approval rituximab + bortezomib Sensitive : A1	rituximab + bortezomib Sensitive: A1 - Approval rituximab + bortezomib Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	bortezomib Sensitive: A1 - Approval bortezomib Sensitive : A1	bortezomib Sensitive: A1 - Approval bortezomib Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	lenalidomide + bortezomib Sensitive: A2 - Guideline lenalidomide + bortezomib Sensitive : A2	lenalidomide + bortezomib Sensitive: A2 - Guideline lenalidomide + bortezomib Sensitive : A2
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	bortezomib + elotuzumab Sensitive: A2 - Guideline bortezomib + elotuzumab Sensitive : A2	bortezomib + elotuzumab Sensitive: A2 - Guideline bortezomib + elotuzumab Sensitive : A2
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	ixazomib Sensitive: A2 - Guideline ixazomib Sensitive : A2	ixazomib Sensitive: A2 - Guideline ixazomib Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	bortezomib Sensitive: A2 - Guideline bortezomib Sensitive : A2	bortezomib Sensitive: A2 - Guideline bortezomib Sensitive : A2
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	bortezomib Sensitive: A2 - Guideline bortezomib Sensitive : A2	bortezomib Sensitive: A2 - Guideline bortezomib Sensitive : A2
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: A2 - Guideline rituximab + ixazomib Sensitive : A2	rituximab + ixazomib Sensitive: A2 - Guideline rituximab + ixazomib Sensitive : A2
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	rituximab + bortezomib Sensitive: A2 - Guideline rituximab + bortezomib Sensitive : A2	rituximab + bortezomib Sensitive: A2 - Guideline rituximab + bortezomib Sensitive : A2
No biomarker	Childhood B Acute Lymphoblastic Leukemia	No biomarker	Childhood B Acute Lymphoblastic Leukemia	bortezomib Sensitive: A2 - Guideline bortezomib Sensitive : A2	bortezomib Sensitive: A2 - Guideline bortezomib Sensitive : A2
No biomarker	Kaposi Sarcoma	No biomarker	Kaposi Sarcoma	bortezomib Sensitive: A2 - Guideline bortezomib Sensitive : A2	bortezomib Sensitive: A2 - Guideline bortezomib Sensitive : A2
Chr del(17)(p13)	Multiple Myeloma	Chr del(17)(p13)	Multiple Myeloma	bortezomib Sensitive: A2 - Guideline bortezomib Sensitive : A2	bortezomib Sensitive: A2 - Guideline bortezomib Sensitive : A2
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	bortezomib Sensitive: A2 - Guideline bortezomib Sensitive : A2	bortezomib Sensitive: A2 - Guideline bortezomib Sensitive : A2
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	ixazomib + pomalidomide Sensitive: A2 - Guideline ixazomib + pomalidomide Sensitive : A2	ixazomib + pomalidomide Sensitive: A2 - Guideline ixazomib + pomalidomide Sensitive : A2
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	selinexor + carfilzomib Sensitive: A2 - Guideline selinexor + carfilzomib Sensitive : A2	selinexor + carfilzomib Sensitive: A2 - Guideline selinexor + carfilzomib Sensitive : A2
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	bortezomib Sensitive: A2 - Guideline bortezomib Sensitive : A2	bortezomib Sensitive: A2 - Guideline bortezomib Sensitive : A2
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	carfilzomib + pomalidomide Sensitive: A2 - Guideline carfilzomib + pomalidomide Sensitive : A2	carfilzomib + pomalidomide Sensitive: A2 - Guideline carfilzomib + pomalidomide Sensitive : A2
Chr t(11;14)	Multiple Myeloma	Chr t(11;14)	Multiple Myeloma	venetoclax + bortezomib Sensitive: B - Late Trials venetoclax + bortezomib Sensitive : B	venetoclax + bortezomib Sensitive: B - Late Trials venetoclax + bortezomib Sensitive : B
Chr del(17p)	Multiple Myeloma	Chr del(17p)	Multiple Myeloma	bortezomib + selinexor Sensitive: B - Late Trials bortezomib + selinexor Sensitive : B	bortezomib + selinexor Sensitive: B - Late Trials bortezomib + selinexor Sensitive : B
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	venetoclax + bortezomib + dexamethasone Sensitive: B - Late Trials venetoclax + bortezomib + dexamethasone Sensitive : B	venetoclax + bortezomib + dexamethasone Sensitive: B - Late Trials venetoclax + bortezomib + dexamethasone Sensitive : B
RPL5 expression	Multiple Myeloma	RPL5 expression	Multiple Myeloma	bortezomib Sensitive: B - Late Trials bortezomib Sensitive : B	bortezomib Sensitive: B - Late Trials bortezomib Sensitive : B
CXCR4 mutation	Waldenstrom Macroglobulinemia	CXCR4 mutation	Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C2 – Inclusion Criteria rituximab + ixazomib Sensitive : C2	rituximab + ixazomib Sensitive: C2 – Inclusion Criteria rituximab + ixazomib Sensitive : C2
MYD88 L265P	Waldenstrom Macroglobulinemia	MYD88 L265P	Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C2 – Inclusion Criteria rituximab + ixazomib Sensitive : C2	rituximab + ixazomib Sensitive: C2 – Inclusion Criteria rituximab + ixazomib Sensitive : C2
Chr del(17p)	Multiple Myeloma	Chr del(17p)	Multiple Myeloma	bortezomib Sensitive: C2 – Inclusion Criteria bortezomib Sensitive : C2	bortezomib Sensitive: C2 – Inclusion Criteria bortezomib Sensitive : C2
Chr t(14;16)	Multiple Myeloma	Chr t(14;16)	Multiple Myeloma	ixazomib Sensitive: C2 – Inclusion Criteria ixazomib Sensitive : C2	ixazomib Sensitive: C2 – Inclusion Criteria ixazomib Sensitive : C2
CXCR4 G336X	Waldenstrom Macroglobulinemia	CXCR4 G336X	Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C3 – Early Trials rituximab + ixazomib Sensitive : C3	rituximab + ixazomib Sensitive: C3 – Early Trials rituximab + ixazomib Sensitive : C3

Proteasome inhibitor

Proteasome inhibitor

Associations(149)

Associations
(149)